Bosh sahifaALNOV • EPA
Novacyt SA
0,58 €
22-noy, 18:00:00 (GMT+1) · EUR · EPA · Ogohlantirish
AksiyalarFR qimmatli qogʻozi
Yopilish kursi
0,58 €
Kunlik diapazon
0,57 € - 0,59 €
Yillik diapazon
0,49 € - 1,59 €
Bozor kapitalizatsiyasi
40,30 mln EUR
Oʻrtacha hajm
299,24 ming
Narx/foyda
-
Dividend daromadliligi
-
Asosiy maydon
EPA
Bozor yangiliklari
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(GBP)iyn, 2024Y/Y qiyosi
Daromad
5,16 mln209,13%
Joriy xarajat
7,92 mln92,89%
Sof foyda
-8,85 mln-112,01%
Sof foyda marjasi
-171,4731,41%
Har bir ulushga tushum
EBITDA
-12,02 mln-324,07%
Amaldagi soliq stavkasi
1,22%
Jami aktivlari
Jami passivlari
(GBP)iyn, 2024Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
32,95 mln-59,69%
Jami aktivlari
99,40 mln-24,78%
Jami passivlari
28,99 mln16,70%
Umumiy kapital
70,41 mln
Tarqatilgan aksiyalar
70,63 mln
Narxi/balansdagi bahosi
0,58
Aktivlardan daromad
-36,30%
Kapitaldan daromad
-43,18%
Naqd pulning sof oʻzgarishi
(GBP)iyn, 2024Y/Y qiyosi
Sof foyda
-8,85 mln-112,01%
Operatsiyalardan naqd pul
-4,54 mln-59,67%
Sarmoyadan naqd pul
-566,50 ming-212,18%
Moliyadan naqd pul
-430,50 ming-61,24%
Naqd pulning sof oʻzgarishi
-5,56 mln-112,16%
Boʻsh pul
-17,73 mln-943,16%
Haqida
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
Tashkil etilgan
2006
Xodimlar soni
240
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu